Zacks: Brokerages Anticipate Eli Lilly and Company (NYSE:LLY) Will Post Earnings of $1.93 Per Share

Analysts forecast that Eli Lilly and Company (NYSE:LLYGet Rating) will announce earnings per share (EPS) of $1.93 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Eli Lilly and’s earnings, with the highest EPS estimate coming in at $2.12 and the lowest estimate coming in at $1.81. Eli Lilly and posted earnings of $1.87 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.2%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Eli Lilly and will report full-year earnings of $8.34 per share for the current year, with EPS estimates ranging from $8.15 to $8.80. For the next financial year, analysts expect that the business will report earnings of $9.56 per share, with EPS estimates ranging from $9.00 to $9.86. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The company had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same period in the prior year, the business earned $1.87 earnings per share. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year.

Several research analysts have recently issued reports on the company. Bank of America upped their price objective on Eli Lilly and from $300.00 to $315.00 in a research note on Thursday, March 17th. Mizuho boosted their price objective on shares of Eli Lilly and from $315.00 to $356.00 in a research note on Monday, May 2nd. Wells Fargo & Company increased their price objective on Eli Lilly and from $280.00 to $305.00 in a report on Friday, April 29th. Daiwa Capital Markets started coverage on Eli Lilly and in a research note on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price target for the company. Finally, Morgan Stanley lifted their price objective on Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $302.56.

In other news, major shareholder Lilly Endowment Inc sold 139,045 shares of the stock in a transaction dated Friday, April 8th. The shares were sold at an average price of $310.79, for a total value of $43,213,795.55. Following the completion of the sale, the insider now owns 105,573,810 shares in the company, valued at $32,811,284,409.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Ilya Yuffa sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $237.45, for a total transaction of $237,450.00. The disclosure for this sale can be found here. Insiders sold a total of 1,088,551 shares of company stock valued at $307,943,730 over the last ninety days. 0.12% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Wagner Wealth Management LLC lifted its position in shares of Eli Lilly and by 59.4% during the 3rd quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock valued at $28,000 after buying an additional 41 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in Eli Lilly and in the 4th quarter worth approximately $28,000. HWG Holdings LP purchased a new position in Eli Lilly and in the 4th quarter valued at approximately $28,000. Icapital Wealth LLC purchased a new position in Eli Lilly and in the 1st quarter valued at approximately $28,000. Finally, Leverty Financial Group LLC bought a new stake in Eli Lilly and during the 4th quarter valued at $29,000. 82.75% of the stock is owned by institutional investors.

Eli Lilly and stock opened at $296.90 on Friday. The company has a market capitalization of $282.10 billion, a PE ratio of 43.99, a P/E/G ratio of 2.33 and a beta of 0.40. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 1.60. The stock has a 50-day moving average price of $286.06 and a two-hundred day moving average price of $264.83. Eli Lilly and has a 12 month low of $191.75 and a 12 month high of $314.00.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Stockholders of record on Monday, May 16th will be paid a $0.98 dividend. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 annualized dividend and a dividend yield of 1.32%. Eli Lilly and’s dividend payout ratio is presently 58.07%.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.